Collected Dataset / CPDDN_PhaseII_DemyelinatingChildren_Follow-up_6months

The population is composed of Canadian children aged younger than 16 years who presented with acquired demyelinating syndrome (ADS), to any of the 16 paediatric health-care facilities or seven regional health-care facilities in Canada or in the United States of America and were enrolled within 90 days of symptom onset.

Information was collected from participants and/or guardian through interviews which collected information about medications, smoke exposure, travel history, family, education. Additionally, questionnaires were used to collect the KIDSCREEN, PedsQL, MSQoL54 (in MS children), BASC and BRIEF. The following neurocognitive tests were administered in-person by a trained neuropsychometrist: D-KEFS, TOMAL-2, WASI, Grooved Pegboard Test, SDMT, BEERY VMI, WJ-III. Clinicians provided information on medication usage, episodes, and conducted a neurological exam. Neurocognitive batteries were conducted in-person. MRI data were also collected. Blood was collected for serum, DNA and PBMCs.